 | • レポートコード：MRC2211A113 • 出版社/出版日：Transparency Market Research / 2022年9月 • レポート形態：英文、PDF、225ページ • 納品方法：Eメール • 産業分類：医療 |
| Single User | ￥857,660 (USD5,795) | ▷ お問い合わせ |
| Multi User | ￥1,301,660 (USD8,795) | ▷ お問い合わせ |
| Corporate License | ￥1,745,660 (USD11,795) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| トレンスペアレンシーマーケットリサーチ社の当調査レポートでは、世界のがんバイオマーカー市場を総合的に調査・分析し、序論、仮定・調査手法、エグゼクティブサマリー、市場概要、キーインサイト、種類別（タンパク質、遺伝子、その他）分析、がん種類別（肺がん、乳がん、白血病、黒色腫、その他）分析、プロファイリング技術別（オミクス、イメージング、イムノアッセイ、バイオインフォマティクス、その他）分析、用途別（診断、研究開発、予知、その他）分析、地域別（北米、ヨーロッパ、アジア太平洋、中南米、中東・アフリカ）分析、競争状況などの内容を掲載しています。なお、当書には、F. Hoffmann-LA Roche Ltd.、Thermo Fisher Scientific, Inc.、Abbott Laboratories、Bristol-Myers Squibb Company、PerkinElmer, Inc.、Qiagen N.V.、Siemens AG、Exact Sciences Corporation、Novartis AG、Bio-Rad Laboratories、Illumina、Agilent Technologies Inc.などの企業情報が含まれています。 ・序論 ・仮定・調査手法 ・エグゼクティブサマリー ・市場概要 ・キーインサイト ・世界のがんバイオマーカー市場規模：種類別 - タンパク質タイプの市場規模 - 遺伝子タイプの市場規模 - その他がんバイオマーカーの市場規模 ・世界のがんバイオマーカー市場規模：がん種類別 - 肺がんにおける市場規模 - 乳がんにおける市場規模 - 白血病における市場規模 - 黒色腫における市場規模 - その他がんにおける市場規模 ・世界のがんバイオマーカー市場規模：プロファイリング技術別 - オミクス技術の市場規模 - イメージング技術の市場規模 - イムノアッセイ技術の市場規模 - バイオインフォマティクス技術の市場規模 - その他技術の市場規模 ・世界のがんバイオマーカー市場規模：用途別 - 診断における市場規模 - 研究開発における市場規模 - 予知における市場規模 - その他用途における市場規模 ・世界のがんバイオマーカー市場規模：地域別 - 北米のがんバイオマーカー市場規模 - ヨーロッパのがんバイオマーカー市場規模 - アジア太平洋のがんバイオマーカー市場規模 - 中南米のがんバイオマーカー市場規模 - 中東・アフリカのがんバイオマーカー市場規模 ・競争状況 |
Cancer Biomarkers Market – Scope of Report
TMR’s report on the global cancer biomarkers market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2022 to 2031. The report provides revenue of the global cancer biomarkers market for the period 2017–2031, considering 2021 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global cancer biomarkers market from 2022 to 2031.
The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the cancer biomarkers market.
Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global cancer biomarkers market.
The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report sheds light on the changing competitive dynamics in the global cancer biomarkers market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global cancer biomarkers market.
The report delves into the competitive landscape of the global cancer biomarkers market. Key players operating in the global cancer biomarkers market have been identified and each one of these has been profiled, in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are attributes of players in the global cancer biomarkers market profiled in this report.
RESEARCH METHODOLOGY
The research methodology will be a combination of exhaustive primary and secondary research to analyze the market cancer biomarkers.
Secondary Research
Secondary research includes a search of company literature, technical writing, patent data, Internet sources, and statistical data from government websites, trade associations, and agencies. This has proven to be the most reliable, effective, and successful approach for obtaining precise data, capturing industry participants’ insights, and recognizing business opportunities.
Secondary research sources that we typically refer, but are not limited to:
Company websites, presentations, annual reports, white papers, technical paper, product brochure
Internal and external proprietary databases and relevant patents
National government documents, statistical databases, and market reports
News articles, press releases, and webcasts specific to companies operating in the market
Specific Secondary Sources:
Industry Sources:
WorldWideScience.org
Elsevier, Inc.
National Institutes of Health (NIH)
PubMed
NCBI
Department of Health Care Service
Trade Data Sources
Trade Map
UN Comtrade
Trade Atlas
Company Information
OneSource Business Browser
Hoover’s
Factiva
Bloomberg
Mergers & Acquisitions
Thomson Mergers & Acquisitions
MergerStat
Profound
Primary Research
During the course of research, we conduct in-depth interviews and discussions with a wide range of key industry participants and opinion leaders. Primary research represents bulk of research efforts, supplemented by extensive secondary research.
We conduct primary interviews on the ongoing basis with industry participants and commentators to validate data and analysis. A typical research interview fulfills the following functions:
Provides first-hand information on market size, market trends, growth trends, competitive landscape, outlook, etc.
Helps in validating and strengthening secondary research findings
Further develops the analysis team’s expertise and market understanding
Primary research involves e-mail interactions, telephonic interviews, as well as face-to-face interviews for each market, category, segment, and sub-segment across geographies
Participants who typically take part in such a process include, but are not limited to:
Industry participants: Marketing/product managers, market intelligence managers, and regional sales managers
Purchasing/Sourcing managers, technical personnel, distributors
Outside experts: Investment bankers, valuation experts, and research analysts specializing in specific markets
Key opinion leaders specializing in different areas corresponding to different industry verticals
List of primary participants, but not limited to:
Advanced Oncotherapy PLC
Danfysik A/S
Hitachi, Ltd.
IBA Worldwide
Mevion Medical Systems, Inc.
Data Triangulation: Information culled from “Secondary & Primary Sources” is cross-checked with “TMR Knowledge Repository”, which is updated every quarter.
Market Estimation: Market size estimations involved in-depth study of product features, technology updates, geographic presence, product demand, sales data (value or volume), historical year-on-year growth, and others. Other approaches were also utilized to derive market size and forecasts. Where no hard data was available, we employed modeling techniques in order to produce comprehensive datasets. A rigorous methodology has been adopted, wherein the available hard data are cross-referenced with the following data types to produce estimates:
Demographic Data: Healthcare expenditure, inflation rates, and others
Industry Indicators: R&D investment, technology stage, and infrastructure, sector growth, and facilities
Market Forecasting: Market forecasts for various segments are derived taking into account drivers, restraints/challenges, and opportunities prevailing in the market and considering advantages/disadvantages of segments/sub-segments over other segments/sub-segments. Business environment, historical sales pattern, unmet needs, competitive intensity, and country-wise surgery data are some of the other pivotal factors, which are considered to derive market forecasts.
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Cancer Biomarkers Market
4. Market Overview
4.1. Introduction
4.1.1. Segment Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Cancer Biomarkers Market Analysis and Forecasts, 2017 – 2031
4.4.1. Market Revenue Projections (US$ Mn)
5. Key Insights
5.1. Technological Advancements
5.2. Key Industry Events (Mergers, Acquisitions, Partnerships, etc.)
5.3. Regulatory Scenario by Region/Globally
5.4. COVID-19 Pandemic Impact on Industry (Value Chain and Short / Mid / Long Term Impact)
6. Global Cancer Biomarkers Market Analysis and Forecasts, By Type
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast By Type, 2017 – 2031
6.3.1. Protein
6.3.2. Genetic
6.3.3. Others
6.4. Market Attractiveness By Type
7. Global Cancer Biomarkers Market Analysis and Forecasts, By Type of Cancer
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast By Type of Cancer, 2017 – 2031
7.3.1. Lung
7.3.2. Breast
7.3.3. Leukemia
7.3.4. Melanoma
7.3.5. Colorectal
7.3.6. Prostate
7.3.7. Ovarian
7.3.8. Liver
7.3.9. Others
7.4. Market Attractiveness By Type of Cancer
8. Global Cancer Biomarkers Market Analysis and Forecasts, By Profiling Technology
8.1. Introduction & Definition
8.2. Key Findings / Developments
8.3. Market Value Forecast By Profiling Technology, 2017 – 2031
8.3.1. Omics
8.3.2. Imaging
8.3.3. Immunoassay
8.3.4. Bioinformatics
8.3.5. Others
8.4. Market Attractiveness By Profiling Technology
9. Global Cancer Biomarkers Market Analysis and Forecasts, By Application
9.1. Introduction & Definition
9.2. Key Findings / Developments
9.3. Market Value Forecast By Application, 2017 – 2031
9.3.1. Diagnostics
9.3.2. R&D
9.3.3. Prognostics
9.3.4. Others
9.4. Market Attractiveness By Application
10. Global Cancer Biomarkers Market Analysis and Forecasts, By Region
10.1. Key Findings
10.2. Market Value Forecast By Region
10.2.1. North America
10.2.2. Europe
10.2.3. Asia Pacific
10.2.4. Latin America
10.2.5. Middle East & Africa
10.3. Market Attractiveness By Country/Region
11. North America Cancer Biomarkers Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast By Type, 2017 – 2031
11.2.1. Protein
11.2.2. Genetic
11.2.3. Others
11.3. Market Value Forecast By Type of Cancer, 2017 – 2031
11.3.1. Lung
11.3.2. Breast
11.3.3. Leukemia
11.3.4. Melanoma
11.3.5. Colorectal
11.3.6. Prostate
11.3.7. Ovarian
11.3.8. Liver
11.3.9. Others
11.4. Market Value Forecast By Profiling Technology, 2017 – 2031
11.4.1. Omics
11.4.2. Imaging
11.4.3. Immunoassay
11.4.4. Bioinformatics
11.4.5. Others
11.5. Market Value Forecast By Application, 2017 – 2031
11.5.1. Diagnostics
11.5.2. R&D
11.5.3. Prognostics
11.5.4. Others
11.6. Market Value Forecast By Country, 2017 – 2031
11.6.1. U.S.
11.6.2. Canada
11.7. Market Attractiveness Analysis
11.7.1. By Type
11.7.2. By Type of Cancer
11.7.3. By Profiling Technology
11.7.4. By Application
11.7.5. By Country
12. Europe Cancer Biomarkers Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast By Type, 2017 – 2031
12.2.1. Protein
12.2.2. Genetic
12.2.3. Others
12.3. Market Value Forecast By Type of Cancer, 2017 – 2031
12.3.1. Lung
12.3.2. Breast
12.3.3. Leukemia
12.3.4. Melanoma
12.3.5. Colorectal
12.3.6. Prostate
12.3.7. Ovarian
12.3.8. Liver
12.3.9. Others
12.4. Market Value Forecast By Profiling Technology, 2017 – 2031
12.4.1. Omics
12.4.2. Imaging
12.4.3. Immunoassay
12.4.4. Bioinformatics
12.4.5. Others
12.5. Market Value Forecast By Application, 2017 – 2031
12.5.1. Diagnostics
12.5.2. R&D
12.5.3. Prognostics
12.5.4. Others
12.6. Market Value Forecast By Country/Sub-region, 2017 – 2031
12.6.1. Germany
12.6.2. U.K.
12.6.3. France
12.6.4. Spain
12.6.5. Italy
12.6.6. Rest of Europe
12.7. Market Attractiveness Analysis
12.7.1. By Type
12.7.2. By Type of Cancer
12.7.3. By Profiling Technology
12.7.4. By Application
12.7.5. By Country/Sub-region
13. Asia Pacific Cancer Biomarkers Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast By Type, 2017 – 2031
13.2.1. Protein
13.2.2. Genetic
13.2.3. Others
13.3. Market Value Forecast By Type of Cancer, 2017 – 2031
13.3.1. Lung
13.3.2. Breast
13.3.3. Leukemia
13.3.4. Melanoma
13.3.5. Colorectal
13.3.6. Prostate
13.3.7. Ovarian
13.3.8. Liver
13.3.9. Others
13.4. Market Value Forecast By Profiling Technology, 2017 – 2031
13.4.1. Omics
13.4.2. Imaging
13.4.3. Immunoassay
13.4.4. Bioinformatics
13.4.5. Others
13.5. Market Value Forecast By Application, 2017 – 2031
13.5.1. Diagnostics
13.5.2. R&D
13.5.3. Prognostics
13.5.4. Others
13.6. Market Value Forecast By Country/Sub-region, 2017 – 2031
13.6.1. China
13.6.2. Japan
13.6.3. India
13.6.4. Australia & New Zealand
13.6.5. Rest of Asia Pacific
13.7. Market Attractiveness Analysis
13.7.1. By Type
13.7.2. By Type of Cancer
13.7.3. By Profiling Technology
13.7.4. By Application
13.7.5. By Country/Sub-region
14. Latin America Cancer Biomarkers Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast By Type, 2017 – 2031
14.2.1. Protein
14.2.2. Genetic
14.2.3. Others
14.3. Market Value Forecast By Type of Cancer, 2017 – 2031
14.3.1. Lung
14.3.2. Breast
14.3.3. Leukemia
14.3.4. Melanoma
14.3.5. Colorectal
14.3.6. Prostate
14.3.7. Ovarian
14.3.8. Liver
14.3.9. Others
14.4. Market Value Forecast By Profiling Technology, 2017 – 2031
14.4.1. Omics
14.4.2. Imaging
14.4.3. Immunoassay
14.4.4. Bioinformatics
14.4.5. Others
14.5. Market Value Forecast By Application, 2017 – 2031
14.5.1. Diagnostics
14.5.2. R&D
14.5.3. Prognostics
14.5.4. Others
14.6. Market Value Forecast By Country/Sub-region, 2017 – 2031
14.6.1. Brazil
14.6.2. Mexico
14.6.3. Rest of Latin America
14.7. Market Attractiveness Analysis
14.7.1. By Type
14.7.2. By Type of Cancer
14.7.3. By Profiling Technology
14.7.4. By Application
14.7.5. By Country/Sub-region
15. Middle East & Africa Cancer Biomarkers Market Analysis and Forecast
15.1. Introduction
15.1.1. Key Findings
15.2. Market Value Forecast By Type, 2017 – 2031
15.2.1. Protein
15.2.2. Genetic
15.2.3. Others
15.3. Market Value Forecast By Type of Cancer, 2017 – 2031
15.3.1. Lung
15.3.2. Breast
15.3.3. Leukemia
15.3.4. Melanoma
15.3.5. Colorectal
15.3.6. Prostate
15.3.7. Ovarian
15.3.8. Liver
15.3.9. Others
15.4. Market Value Forecast By Profiling Technology, 2017 – 2031
15.4.1. Omics
15.4.2. Imaging
15.4.3. Immunoassay
15.4.4. Bioinformatics
15.4.5. Others
15.5. Market Value Forecast By Application, 2017 – 2031
15.5.1. Diagnostics
15.5.2. R&D
15.5.3. Prognostics
15.5.4. Others
15.6. Market Value Forecast By Country/Sub-region, 2017 – 2031
15.6.1. GCC Countries
15.6.2. South Africa
15.6.3. Rest of Middle East & Africa
15.7. Market Attractiveness Analysis
15.7.1. By Type
15.7.2. By Type of Cancer
15.7.3. By Profiling Technology
15.7.4. By Application
15.7.5. By Country/Sub-region
16. Competition Landscape
16.1. Market Player – Competition Matrix (By Tier and Size of companies)
16.2. Market Share/Ranking Analysis By Company (2021)
16.3. Company Profiles
16.3.1. F. Hoffmann-LA Roche Ltd.
16.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.1.2. Product Portfolio
16.3.1.3. SWOT Analysis
16.3.1.4. Strategic Overview
16.3.2. Thermo Fisher Scientific, Inc.
16.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.2.2. Product Portfolio
16.3.2.3. SWOT Analysis
16.3.2.4. Strategic Overview
16.3.3. Abbott Laboratories
16.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.3.2. Product Portfolio
16.3.3.3. SWOT Analysis
16.3.3.4. Strategic Overview
16.3.4. Bristol-Myers Squibb Company
16.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.4.2. Product Portfolio
16.3.4.3. SWOT Analysis
16.3.4.4. Strategic Overview
16.3.5. PerkinElmer, Inc.
16.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.5.2. Product Portfolio
16.3.5.3. SWOT Analysis
16.3.5.4. Strategic Overview
16.3.6. Qiagen N.V.
16.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.6.2. Product Portfolio
16.3.6.3. SWOT Analysis
16.3.6.4. Strategic Overview
16.3.7. Siemens AG
16.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.7.2. Product Portfolio
16.3.7.3. SWOT Analysis
16.3.7.4. Strategic Overview
16.3.8. Exact Sciences Corporation
16.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.8.2. Product Portfolio
16.3.8.3. SWOT Analysis
16.3.8.4. Strategic Overview
16.3.9. Novartis AG
16.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.9.2. Product Portfolio
16.3.9.3. SWOT Analysis
16.3.9.4. Strategic Overview
16.3.10. Bio-Rad Laboratories
16.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.10.2. Product Portfolio
16.3.10.3. SWOT Analysis
16.3.10.4. Strategic Overview
16.3.11. Illumina
16.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.11.2. Product Portfolio
16.3.11.3. SWOT Analysis
16.3.11.4. Strategic Overview
16.3.12. Agilent Technologies Inc.
16.3.12.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.12.2. Product Portfolio
16.3.12.3. SWOT Analysis
16.3.12.4. Strategic Overview
16.3.13. Hologic, Inc.
16.3.13.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.13.2. Product Portfolio
16.3.13.3. SWOT Analysis
16.3.13.4. Strategic Overview
16.3.14. bioMérieux SA
16.3.14.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.14.2. Product Portfolio
16.3.14.3. SWOT Analysis
16.3.14.4. Strategic Overview
Table 01: Global Cancer Biomarkers Market Value (US$ Mn) Forecast, by Type, 2017‒2031
Table 02: Global Cancer Biomarkers Market Value (US$ Mn) Forecast, by Type of Cancer, 2017–2031
Table 03: Global Cancer Biomarkers Market Value (US$ Mn) Forecast, by Technology, 2017–2031
Table 04: Global Cancer Biomarkers Market Value (US$ Mn) Forecast, by Application, 2017–2031
Table 05: Global Cancer Biomarkers Market Value (US$ Mn) Forecast, by Region, 2017–2031
Table 06: North America Cancer Biomarkers Market Value (US$ Mn) Forecast, by Country, 2017–2031
Table 07: North America Cancer Biomarkers Market Value (US$ Mn) Forecast, by Type, 2017‒2031
Table 08: North America Cancer Biomarkers Market Value (US$ Mn) Forecast, by Type of Cancer, 2017–2031
Table 09: North America Cancer Biomarkers Market Value (US$ Mn) Forecast, by Technology, 2017–2031
Table 10: North America Cancer Biomarkers Market Value (US$ Mn) Forecast, by Application, 2017–2031
Table 11: Europe Cancer Biomarkers Market Value (US$ Mn) Forecast, by Country/Sub-Region, 2017–2031
Table 12: Europe Cancer Biomarkers Market Value (US$ Mn) Forecast, by Type, 2017‒2031
Table 13: Europe Cancer Biomarkers Market Value (US$ Mn) Forecast, by Type of Cancer, 2017–2031
Table 14: Europe Cancer Biomarkers Market Value (US$ Mn) Forecast, by Technology, 2017–2031
Table 15: Europe Cancer Biomarkers Market Value (US$ Mn) Forecast, by Application, 2017–2031
Table 16: Asia Pacific Cancer Biomarkers Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 17: Asia Pacific Cancer Biomarkers Market Value (US$ Mn) Forecast, by Type, 2017‒2031
Table 18: Asia Pacific Cancer Biomarkers Market Value (US$ Mn) Forecast, by Type of Cancer, 2017–2031
Table 19: Asia Pacific Cancer Biomarkers Market Value (US$ Mn) Forecast, by Technology, 2017–2031
Table 20: Asia Pacific Cancer Biomarkers Market Value (US$ Mn) Forecast, by Application, 2017–2031
Table 21: Latin America Cancer Biomarkers Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
Table 22: Latin America Cancer Biomarkers Market Value (US$ Mn) Forecast, by Type, 2017‒2031
Table 23: Latin America Cancer Biomarkers Market Value (US$ Mn) Forecast, by Type of Cancer, 2017–2031
Table 24: Latin America Cancer Biomarkers Market Value (US$ Mn) Forecast, by Technology, 2017–2031
Table 25: Latin America Cancer Biomarkers Market Value (US$ Mn) Forecast, by Application, 2017–2031
Table 26: Middle East & Africa Cancer Biomarkers Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
Table 27: Middle East & Africa Cancer Biomarkers Market Value (US$ Mn) Forecast, by Type, 2017‒2031
Table 28: Middle East & Africa Cancer Biomarkers Market Value (US$ Mn) Forecast, by Type of Cancer, 2017–2031
Table 29: Middle East & Africa Cancer Biomarkers Market Value (US$ Mn) Forecast, by Technology, 2017–2031
Table 30: Middle East & Africa Cancer Biomarkers Market Value (US$ Mn) Forecast, by Application, 2017–2031